Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10967068 | Vaccine | 2013 | 4 Pages |
Abstract
Review of VAERS reports did not identify any new or unexpected safety concerns after TIV-ID. Injection site reactions were the most commonly reported AEs, similar to the pre-licensure clinical trials. Use of TIV-ID in younger and older individuals outside the approved age range highlights the need for education of healthcare providers regarding approved TIV-ID use.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pedro L. Moro, Theresa Harrington, Tom Shimabukuro, Maria Cano, Oidda I. Museru, David Menschik, Karen Broder,